Directed Evolution of Seneca Valley Virus in Tumorsphere and Monolayer Cell Cultures of a Small-Cell Lung Cancer Model

Author:

Waqqar Shakeel1,Lee Kai1,Lawley Blair1,Bilton Timothy2,Quiñones-Mateu Miguel E.1ORCID,Bostina Mihnea1ORCID,Burga Laura N.1

Affiliation:

1. Department of Microbiology and Immunology, University of Otago, Dunedin 9016, New Zealand

2. Invermay Agricultural Centre, AgResearch, Mosgiel 9092, New Zealand

Abstract

The Seneca Valley virus (SVV) is an oncolytic virus from the picornavirus family, characterized by a 7.3-kilobase RNA genome encoding for all the structural and functional viral proteins. Directed evolution by serial passaging has been employed for oncolytic virus adaptation to increase the killing efficacy towards certain types of tumors. We propagated the SVV in a small-cell lung cancer model under two culture conditions: conventional cell monolayer and tumorspheres, with the latter resembling more closely the cellular structure of the tumor of origin. We observed an increase of the virus-killing efficacy after ten passages in the tumorspheres. Deep sequencing analyses showed genomic changes in two SVV populations comprising 150 single nucleotides variants and 72 amino acid substitutions. Major differences observed in the tumorsphere-passaged virus population, compared to the cell monolayer, were identified in the conserved structural protein VP2 and in the highly variable P2 region, suggesting that the increase in the ability of the SVV to kill cells over time in the tumorspheres is acquired by capsid conservation and positively selecting mutations to counter the host innate immune responses.

Funder

Webster Family Chair in Viral Pathogenesis, University of Otago, the Ministry of Health, New Zealand

COVID-19 Innovation Acceleration Fund, Ministry of Business, Innovation & Employment (MBIE), New Zealand

University of Otago research grant

University of Otago PhD scholarship

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference102 articles.

1. Viruses and human cancer;Liao;Yale J. Biol. Med.,2006

2. Oncolytic viruses for cancer immunotherapy;Hemminki;J. Hematol. Oncol.,2020

3. Oncolytic Viruses: Priming Time for Cancer Immunotherapy;Russell;BioDrugs,2019

4. Oncolytic virus therapy: A new era of cancer treatment at dawn;Fukuhara;Cancer Sci.,2016

5. Mechanisms of immunomodulation by mammalian and viral decoy receptors: Insights from structures;Felix;Nat. Rev. Immunol.,2017

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3